Drug intelligence / Profile preview

XPACE-2001

Development stage: Preclinical
Lead developer: Xanadu Bio
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics

Overview

XPACE-2001 is a preclinical prophylactic mRNA vaccine candidate targeting the SARS-CoV-2 spike (S) protein for the prevention of COVID-19, developed by Xanadu Bio.[4] As an mRNA vaccine, it is designed to deliver nucleoside-encoded instructions for host cells to produce the viral spike antigen, thereby inducing neutralizing antibody and cellular immune responses against SARS-CoV-2.[1][4] The program is positioned within Xanadu Bio’s infectious disease pipeline and has not yet entered clinical development.[4]

Targets

SARS-CoV-2 spike

Beyond the preview

Go deeper on XPACE-2001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on XPACE-2001.

Explore the full profile